The activated form of gelatinase B/matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage

Experimental Eye Research

Volumn 83, Issue 2, 2006, Pages 401-407

  Descamps, Francis J ^a   Martens, Erik ^a   Kangave, Dustan ^b   Struyf, Sofie ^a   Geboes, Karel ^c   Van Damme, Jo ^a   Opdenakker, Ghislain ^a   Abu El Asrar, Ahmed M ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

diabetes; gelatinase B matrix metalloproteinase 9; hemorrhage; retinopathy; vitreous

Indexed keywords

GELATINASE A; GELATINASE B; HEMOGLOBIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DIABETES MELLITUS; DIABETIC RETINOPATHY; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RETINA DETACHMENT; VITRECTOMY; VITREOUS BODY; VITREOUS HEMORRHAGE; ZYMOGRAPHY;

COLLAGENASES; DIABETIC RETINOPATHY; ENZYME ACTIVATION; ENZYME PRECURSORS; EYE PROTEINS; HEMOGLOBINS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; RETINAL DETACHMENT; RETINAL NEOVASCULARIZATION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VITREOUS BODY; VITREOUS HEMORRHAGE;

EID: 33744918292     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2006.01.017     Document Type: Article

References (32)

1. Abu El-Asrar A.M., Dralands L., Veckeneer M., Geboes K., Missotten L., Van Aelst I., and Opdenakker G. Gelatinase B in proliferative vitreoretinal disorders. Am. J. Ophthalmol. 125 (1998) 844-851
2. Baker A.H., Edwards D.R., and Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 115 (2002) 3719-3727
3. Birkedal-Hansen H., Moore W.G., Bodden M.K., Windsor L.J., Birkedal-Hansen B., DeCarlo A., and Engler J.A. Matrix metalloproteinases: a review. Crit. Rev. Oral Biol. Med. 4 (1993) 197-250
4. Bradford M.M. Rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
5. Brown D., Hamdi H., Bahri S., and Kenney M.C. Characterization of an endogenous metalloproteinase in human vitreous. Curr. Eye Res. 13 (1994) 639-647
6. Castellanos M., Leira R., Serena J., Pumar J.M., Lizasoain I., Castillo J., and Davalos A. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 34 (2003) 40-46
7. Crosby W.H., and Furth F.W. A modification of the benzidine method for measurement of hemoglobin in plasma and urine. Blood 114 (1956) 380-383
8. Cuzner M.L., and Opdenakker G. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J. Neuroimmunol. 94 (1999) 1-14
9. Das A., McLamore A., Song W.M., and McGuire P.G. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch. Ophthalmol. 117 (1999) 498-503
10. Davis G.E., Allen K.A.P., Salazar R., and Maxwell S.A. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J. Cell Sci. 114 (2001) 917-930
11. Descamps F.J., Martens E., and Opdenakker G. Analysis of gelatinases in complex biological fluids and tissue extracts. Lab. Invest. 82 (2003) 1607-1608
12. Fong D.S., Aiello L.P., Ferris III F.L., and Klein R. Diabetic retinopathy. Diabetes Care 27 (2004) 2540-2553
13. Giebel S.J., Menicucci G., McGuire P.G., and Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood retinal barrier. Lab. Invest. 85 (2005) 597-607
14. Jin M., Kashiwagi K., Iizuka Y., Tanaka Y., Imai M., and Tsukahara S. Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 21 (2001) 28-33
15. Kosano H., Okano T., Katsura Y., Noritake M., Kado S., Matsuoka T., and Nishigori H. ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci. 64 (1999) 2307-2315
16. Masure S., Billiau A., Van Damme J., and Opdenakker G. Human hepatoma cells produce an 85 kDa gelatinase regulated by phorbol 12-myristate 13-acetate. Biochim. Biophys. Acta. 1054 (1990) 317-325
17. Matrisian L. Matrix metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 6 (1990) 121-125
18. Matsuo T., Okada Y., Shiraga F., and Yanagawa T. TIMP-1 and TIMP-2 levels in vitreous and subretinal fluid. Jpn. J. Ophthalmol. 42 (1998) 377-380
19. Montaner J., Alvarez-Sabin J., Molina C.A., Angles A., Abilleira S., Arenillas J., and Monasterio J. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32 (2001) 2762-2767
20. Montaner J., Molina C.A., Monasterio J., Abilleira S., Arenillas J.F., Ribo M., Quintana M., and Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107 (2003) 598-603
21. Montesano R., and Orci L. Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell 42 (1985) 469-477
22. Moses M.A., Sudhalter J., and Langer R. Identification of an inhibitor of neovascularization from cartilage. Science 248 (1990) 1408-1410
23. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol. Chem. 378 (1997) 151-160
24. Nguyen M., Arkell J., and Jackson C.J. Three-dimensional collagen matrices induce delayed but sustained activation of gelatinase A in human endothelial cells via MT1-MMP. Int. J. Biochem. Cell Biol. 32 (2000) 621-631
25. Nguyen M., Arkell J., and Jackson C.J. Human endothelial gelatinases and angiogenesis. Int. J. Biochem. Cell Biol. 33 (2001) 960-970
26. Noda K., Ishida S., Inoue M., Obata K., Oguchi Y., Okada Y., and Ikeda E. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 44 (2003) 2163-2170
27. Ohno-Matsui K., Uetama T., Yoshida T., Hayano M., Itoh T., Morita I., and Mochizuki M. Reduced retinal angiogenesis in MMP-2-deficient mice. Invest. Ophthalmol. Vis. Sci. 44 (2003) 5370-5375
28. Ramos-DeSimone N., Hahn-Dantona E., Sipley J., Nagase H., French D.L., and Quigley J.P. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 274 (1999) 13066-13076
29. Salzmann J., Limb G.A., Khaw P.T., Gregor Z.J., Webster L., Chignell A.H., and Charteris D.G. Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br. J. Ophthalmol. 84 (2000) 1091-1096
30. Simpson A.J., Booth N.A., Moore N.R., Lewis S.J., and Gray R.S. Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study. Acta. Diabetol. 36 (1999) 155-158
31. Springman E.B., Angleton E.L., Birkedalhansen H., and Van Wart H.E. Multiple-modes of activation of latent human fibroblast collagenase - evidence for the role of a cys-73 active-site zinc complex in latency and a cysteine switch mechanism for activation. Proc. Natl. Acad. Sci. USA. 87 (1990) 364-368
32. Sumii T., and Lo E.H. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33 (2002) 831-836